BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia

Abstract : Approximately 30% of the patients who fulfil the criteria of Waldenström's macroglobulinemia (WM) are diagnosed while asymptomatic (indolent), and will not require immediate therapy. Conversely, patients with a disease-related event will be considered for therapy. The physiopathology of these 2 groups remains unclear, and the mechanisms of progression from indolent to symptomatic WM have yet to be fully understood. Seventeen patients diagnosed with WM were included in this study, 8 asymptomatic WM (A-WM) and 9 symptomatic WM (S-WM). A differential analysis was performed on a first series of 11 patients and identified 48 genes whose expression separated samples from A-to S-WM. This gene signature was then confirmed on a second independent validation set of 6 WM. Within this expression profile, BACH2, a B-cell transcription factor known to be a tumor suppressor gene, was found to be over-expressed in A-MW relatively to S-MW. We specifically over-expressed BACH2 in a WM-related cell line and observed a significant reduction of the clonogenic activity. To the best of our knowledge, we report for the first time a specific gene expression signature that differentiates A-WM and S-WM. Within this expression profile, BACH2 was identified as a candidate gene that may help to understand better the behavior of tumor cells in indolent WM.
Type de document :
Article dans une revue
Oncotarget, Impact journals, 2016
Liste complète des métadonnées

https://hal.inria.fr/hal-01423307
Contributeur : Guillemette Marot <>
Soumis le : jeudi 29 décembre 2016 - 11:29:20
Dernière modification le : mardi 3 juillet 2018 - 11:46:47
Document(s) archivé(s) le : mardi 28 mars 2017 - 01:55:41

Fichier

Herbaux2016.pdf
Publication financée par une institution

Identifiants

  • HAL Id : hal-01423307, version 1

Collections

Citation

Charles Herbaux, Elisabeth Bertrand, Guillemette Marot, Christophe Roumier, Nicolas Poret, et al.. BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia. Oncotarget, Impact journals, 2016. 〈hal-01423307〉

Partager

Métriques

Consultations de la notice

269

Téléchargements de fichiers

54